

Europe
Drug Forecasts 

Europe Drug Forecasts to 2026: Real-world, country level historic product sales and consensus based forecasts.

Conduct European market sizing, R&D horizon scanning and price comparison utilising real world government and company reported sales data with country level, consensus based product forecasts to 2026.



European Market Sizing

Forecasts for key branded products

Model Future Pipeline Impact

Forecasts for full R&D pipeline

Government and Company Reported Drug Sales

Compare with audit based systems

Pricing

Perform comparative pricing analysis

Generic Market Analysis

Generic sales, volume & pricing

European Launch Dates

Launch dates for products in European countries

Single solution for business development and licensing, commercial and corporate strategy, consultants and investment banks



European Market Sizing

Forecasts for key branded drugs at a European country level – market value of over €100bn in 2026

- Conduct future market assessment
- Map future trends of key marketed drugs
- Profile in line products

Model Future Pipeline Impact

Full forecast pipeline for R&D products launching in Europe – market value €30bn

- Map key pipeline assets that are likely to launch by 2026 and measure impact
- Identify new medicines and how they impact therapy areas

Competitive Landscaping

Historical government and company reported sales data (EU 5 and other key markets)


- Compare product performance across key European markets
- Map uptake trends and drivers across European countries
- Understand drug launch timelines across 20 countries

Pricing Comparison Analysis Across Countries


Ex-factory pricing data for Germany, France, Italy, England, Poland, Spain and other key markets

- Perform comparative analysis across EU 6 countries for key products
- Use price/DDD benchmark to inform quick assessment of new assets


Europe Product Forecasts (€m):
Top 5 Brands in 2022 Anti-TNF Products




Europe R&D Product Forecasts:
Monoclonal Antibody Antineoplastics



Sales Market Share within Key Brands:
Monoclonal Antibody Antineoplastics



Manufacturer Price (France) € - Latest
(€) Monoclonal Antibody Antineoplastics



A pioneering methodology for European country level drug forecasts

Powered by Evaluate's industry standard consensus forecasts and broken out on a European country level using:

- European historical data – government and company reported
- Coupled with Evaluate's proprietary methodology inputs:
 - Estimated European launch timelines of R&D products
 - Analogue methodology to model forecast for R&D products
 - European uptake patterns and country launch timings
 - Expected European generic entry



Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalized, expert support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

Evaluate
Omnium provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential.

Evaluate
Pharma offers a global view of the pharmaceutical market's past, present and future performance with consensus forecasts to 2026, company financials, pipelines and deals.

Evaluate
Medtech tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2026, company financials and more.

Evaluate Custom Solutions improves your strategic decision-making with customized solutions and deep insights that draw on our industry expertise and trusted commercial intelligence.

Evaluate Vantage provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate's commercial intelligence.

www.evaluate.com | [@EvaluatePharma](https://twitter.com/EvaluatePharma) [@EvaluateVantage](https://twitter.com/EvaluateVantage)

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom

T +44 (0)20 7377 0800

Evaluate Americas

EvaluatePharma USA Inc.
60 State Street, Suite 1910
Boston, MA 02109
USA

T +1 617 573 9450

Evaluate Asia Pacific

Evaluate Japan KK
Holland Hills Mori Tower 2F
5-11-2 Toranomon, Minato-ku
Tokyo 105-0001, Japan

T +81 (0)80 1164 4754